{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T00:19:47Z","timestamp":1793751587397,"version":"4.6.1"},"reference-count":156,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T00:00:00Z","timestamp":1681344000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["LA\/P\/0140\/2020"],"award-info":[{"award-number":["LA\/P\/0140\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDB\/04378\/2020"],"award-info":[{"award-number":["UIDB\/04378\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDP\/04378\/2020"],"award-info":[{"award-number":["UIDP\/04378\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015621","name":"UCIBIO","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015621","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.bcp.2023.115522","type":"journal-article","created":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T12:42:34Z","timestamp":1680007354000},"page":"115522","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":336,"special_numbering":"C","title":["Alzheimer\u2019s disease: Insights and new prospects in disease pathophysiology, biomarkers and disease-modifying drugs"],"prefix":"10.1016","volume":"211","author":[{"given":"Ana R.","family":"Monteiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Barbosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Remi\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2023.115522_b0005","doi-asserted-by":"crossref","unstructured":"2019 Alzheimer\u2019s disease facts and figures, Alzheimer\u2019s Dement 15:321\u2013387.","DOI":"10.1016\/j.jalz.2019.01.010"},{"key":"10.1016\/j.bcp.2023.115522_b0010","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1177\/1073110518804230","article-title":"Alzheimer disease: Perspectives from epidemiology and genetics","volume":"46","author":"Haines","year":"2018","journal-title":"J. Law Med. Ethics"},{"key":"10.1016\/j.bcp.2023.115522_b0015","unstructured":"B. Duthey, Background Paper 6.11 Alzheimer Disease and other Dementias, Update on 2004. World Heal Organ 1\u201377, 2013."},{"key":"10.1016\/j.bcp.2023.115522_b0020","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41582-018-0032-9","article-title":"Sex differences in Alzheimer disease \u2014 The gateway to precision medicine","volume":"14","author":"Ferretti","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.bcp.2023.115522_b0025","doi-asserted-by":"crossref","first-page":"182","DOI":"10.20344\/amp.6025","article-title":"Estimativa da preval\u00eancia da dem\u00eancia e da doen\u00e7a de Alzheimer em Portugal","volume":"7","author":"Santana","year":"2015","journal-title":"Acta Med. Port."},{"key":"10.1016\/j.bcp.2023.115522_b0030","first-page":"895","article-title":"Lots of people are forgetful. Are there any particular warning signs of Alzheimer\u2019s disease?","volume":"461","author":"Mucke","year":"2009","journal-title":"Neuroscience"},{"key":"10.1016\/j.bcp.2023.115522_b0035","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2741\/E605","article-title":"Genetics of familial and sporadic Alzheimer\u2019s disease","volume":"5","author":"Piaceri","year":"2013","journal-title":"Front Biosci"},{"key":"10.1016\/j.bcp.2023.115522_b0040","doi-asserted-by":"crossref","unstructured":"S. Tiwari, A. Venkata, A. Kaushik, Y. Adriana, M. Nair, Alzheimer \u2019 s Disease Diagnostics And Therapeutics Market. Int J Nanomedicine Jul 2019 (2019) 5541\u20135554.","DOI":"10.2147\/IJN.S200490"},{"key":"10.1016\/j.bcp.2023.115522_b0045","first-page":"1","article-title":"APP, PSEN1, and PSEN2 mutations in early- onset Alzheimer disease : A genetic screening study of familial and sporadic cases","volume":"1","author":"Wallon","year":"2017","journal-title":"PLoS Med."},{"key":"10.1016\/j.bcp.2023.115522_b0050","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph16030337","article-title":"Occupational exposures and neurodegenerative diseases\u2014a systematic literature review and meta-analyses","author":"Gunnarsson","year":"2019","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"10.1016\/j.bcp.2023.115522_b0055","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1194\/jlr.R075481","article-title":"Apolipoprotein E and Alzheimer\u2019s disease: The influence of apolipoprotein E on amyloid-\u03b2 and other amyloidogenic proteins","volume":"58","author":"Huynh","year":"2017","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.bcp.2023.115522_b0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13024-019-0324-6","article-title":"Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer\u2019s disease","volume":"14","author":"Najm","year":"2019","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.bcp.2023.115522_b0065","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.genm.2009.06.004","article-title":"Effects of gender on response to treatment with rivastigmine in mild cognitive impairment: A post hoc statistical modeling approach","volume":"6","author":"Ferris","year":"2009","journal-title":"Gend. Med."},{"key":"10.1016\/j.bcp.2023.115522_b0070","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1474-4422(18)30028-0","article-title":"Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer\u2019s disease: a longitudinal study","volume":"17","author":"Gordon","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.bcp.2023.115522_b0075","doi-asserted-by":"crossref","unstructured":"J.B.J. Kwok, Role of epigenetics in Alzheimer \u2019 s and Parkinson \u2019 s disease R eview. 1 (2010) 671\u2013682.","DOI":"10.2217\/epi.10.43"},{"key":"10.1016\/j.bcp.2023.115522_b0080","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1007\/s12035-016-0357-6","article-title":"Epigenetics in Alzheimer\u2019s Disease: Perspective of DNA Methylation","volume":"55","author":"Qazi","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.bcp.2023.115522_b0085","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1016\/j.neurobiolaging.2008.12.005","article-title":"Epigenetic changes in Alzheimer\u2019s disease: Decrements in DNA methylation","volume":"31","author":"Mastroeni","year":"2010","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.bcp.2023.115522_b0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/eep\/dvx008","article-title":"DNA methylation alterations in Alzheimer\u2019s disease","volume":"3","author":"Yokoyama","year":"2017","journal-title":"Environ Epigenetics"},{"key":"10.1016\/j.bcp.2023.115522_b0095","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.neurobiolaging.2013.02.021","article-title":"Consistent decrease in global DNA methylation and hydroxymethylation in the hippocampus of Alzheimer\u2019s disease patients","volume":"34","author":"Chouliaras","year":"2013","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.bcp.2023.115522_b0100","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.mad.2013.08.005","article-title":"Epigenetic changes in the progression of Alzheimer\u2019s disease","volume":"134","author":"Bradley-Whitman","year":"2013","journal-title":"Mech. Ageing Dev."},{"key":"10.1016\/j.bcp.2023.115522_b0105","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1093\/brain\/awy132","article-title":"The cholinergic system in the pathophysiology and treatment of Alzheimer\u2019s disease","volume":"141","author":"Hampel","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.bcp.2023.115522_b0110","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/jphp.12919","article-title":"Muscarinic and nicotinic acetylcholine receptor agonists: current scenario in Alzheimer\u2019s disease therapy","volume":"70","author":"Verma","year":"2018","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.bcp.2023.115522_b0115","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.conb.2006.09.002","article-title":"The role of acetylcholine in learning and memory","volume":"16","author":"Hasselmo","year":"2006","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.bcp.2023.115522_b0120","first-page":"2","article-title":"Alzheimer\u2019s & Dementia : The Journal of the Alzheimer\u2019s Association Revisiting the cholinergic hypothesis in Alzheimer\u2019s disease : emerging evidence from translational and clinical research","volume":"6","author":"Snyder","year":"2020","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"10.1016\/j.bcp.2023.115522_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.jalz.2016.02.002","article-title":"Preclinical Alzheimer\u2019s disease: Definition, natural history, and diagnostic criteria","author":"Dubois","year":"2016","journal-title":"Alzheimer\u2019s Dement"},{"key":"10.1016\/j.bcp.2023.115522_b0130","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimer\u2019s Dement"},{"key":"10.1016\/j.bcp.2023.115522_b0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnagi.2018.00245","article-title":"Blood-cerebrospinal fluid barrier gradients in mild cognitive impairment and Alzheimer\u2019s disease: Relationship to inflammatory cytokines and chemokines","volume":"10","author":"Ott","year":"2018","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.bcp.2023.115522_b0140","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/s41582-018-0070-3","article-title":"Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer disease","volume":"14","author":"Kivipelto","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.bcp.2023.115522_b0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41398-020-0839-1","article-title":"Depression\u2014an underrecognized target for prevention of dementia in Alzheimer\u2019s disease","volume":"10","author":"Dafsari","year":"2020","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.bcp.2023.115522_b0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40035-018-0107-y","article-title":"Alzheimer\u2019s disease hypothesis and related therapies","volume":"7","author":"Du","year":"2018","journal-title":"Transl Neurodegener"},{"key":"10.1016\/j.bcp.2023.115522_b0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13024-020-00391-7","article-title":"Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer\u2019s disease","volume":"15","author":"Guo","year":"2020","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.bcp.2023.115522_b0160","doi-asserted-by":"crossref","first-page":"437","DOI":"10.4103\/1673-5374.245463","article-title":"Multitarget therapeutic strategies for Alzheimer\u2019s disease","volume":"14","author":"Ibrahim","year":"2019","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.bcp.2023.115522_b0165","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","article-title":"Alzheimer\u2019s disease","volume":"397","author":"Scheltens","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2023.115522_b0170","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1021\/acs.chemrev.8b00138","article-title":"Development of multifunctional molecules as potential therapeutic candidates for Alzheimer\u2019s disease, Parkinson\u2019s disease, and amyotrophic lateral sclerosis in the last decade","volume":"119","author":"Savelieff","year":"2019","journal-title":"Chem. Rev."},{"key":"10.1016\/j.bcp.2023.115522_b0175","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/nrn.2017.29","article-title":"Not just amyloid: Physiological functions of the amyloid precursor protein family","volume":"18","author":"M\u00fcller","year":"2017","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.bcp.2023.115522_b0180","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1146\/annurev-neuro-061010-113613","article-title":"Amyloid precursor protein processing and alzheimer\u2019s disease","volume":"34","author":"O\u2019Brien","year":"2011","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.bcp.2023.115522_b0185","doi-asserted-by":"crossref","first-page":"29615","DOI":"10.1074\/jbc.R800019200","article-title":"Amyloid precursor protein trafficking, processing, and function","volume":"283","author":"Thinakaran","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2023.115522_b0190","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/795375","article-title":"Amyloid beta: Multiple mechanisms of toxicity and only some protective effects?","author":"Carrillo-Mora","year":"2014","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.bcp.2023.115522_b0195","doi-asserted-by":"crossref","unstructured":"N.M. Kanaan, D.S. Himmelstein, S.M. Ward, B. Combs, L.I. Binder, Tau Protein: Biology and Pathobiology, Second Edi. Mov Disord Genet Model Second Ed., 2015. https:\/\/doi.org\/10.1016\/B978-0-12-405195-9.00056-1.","DOI":"10.1016\/B978-0-12-405195-9.00056-1"},{"key":"10.1016\/j.bcp.2023.115522_b0200","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.bbadis.2004.09.008","article-title":"Tau pathology in Alzheimer disease and other tauopathies","volume":"1739","author":"Iqbal","year":"2005","journal-title":"Biochim. Biophys. Acta \u2013 Mol. Basis Dis."},{"key":"10.1016\/j.bcp.2023.115522_b0205","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1460-9568.2006.05226.x","article-title":"Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration","volume":"25","author":"Wang","year":"2007","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.bcp.2023.115522_b0210","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/nan.12084","article-title":"Phosphorylation of tau protein at sites Ser396-404 is one of the earliest events in Alzheimer\u2019s disease and Down syndrome","volume":"40","author":"Mondrag\u00f3n-Rodr\u00edguez","year":"2014","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.bcp.2023.115522_b0215","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1159\/000485580","article-title":"The Key Roles of GSK-3\u03b2 in Regulating Mitochondrial Activity","volume":"44","author":"Yang","year":"2017","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.bcp.2023.115522_b0220","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s11357-019-00085-z","article-title":"An expanding GSK3 network: implications for aging research","volume":"41","author":"Souder","year":"2019","journal-title":"GeroScience"},{"key":"10.1016\/j.bcp.2023.115522_b0225","doi-asserted-by":"crossref","DOI":"10.3390\/antiox8030072","article-title":"Measurement and clinical significance of lipid peroxidation as a biomarker of oxidative stress: Oxidative stress in diabetes, atherosclerosis, and chronic inflammation","author":"Ito","year":"2019","journal-title":"Antioxidants"},{"key":"10.1016\/j.bcp.2023.115522_b0230","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41573-021-00233-1","article-title":"Targeting oxidative stress in disease: promise and limitations of antioxidant therapy","volume":"20","author":"Forman","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2023.115522_b0235","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.freeradbiomed.2009.12.022","article-title":"Reactive oxygen species, cellular redox systems, and apoptosis","volume":"48","author":"Circu","year":"2010","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.bcp.2023.115522_b0240","unstructured":"Y. Zhao, B. Zhao, Review Article Oxidative Stress and the Pathogenesis of Alzheimer \u2019 s Disease. Oxid. Med. Cell. Longev. 2013, 2013."},{"key":"10.1016\/j.bcp.2023.115522_b0245","doi-asserted-by":"crossref","first-page":"797","DOI":"10.2147\/DDDT.S130514","article-title":"Proteinopathy, oxidative stress and mitochondrial dysfunction: Cross talk in alzheimer\u2019s disease and parkinson\u2019s disease","volume":"11","author":"Ganguly","year":"2017","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.bcp.2023.115522_b0250","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1750-3639.2004.tb00087.x","article-title":"Amyloid \u03b2-peptide(1\u201342) contributes to the oxidative stress and neurodegeneration found in Alzheimer disease brain","volume":"14","author":"Butterfield","year":"2004","journal-title":"Brain Pathol."},{"key":"10.1016\/j.bcp.2023.115522_b0255","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.neuroscience.2004.12.022","article-title":"Proteomic identification of proteins specifically oxidized by intracerebral injection of amyloid \u03b2-peptide (1\u201342) into rat brain: Implications for Alzheimer\u2019s disease","volume":"132","author":"Boyd-Kimball","year":"2005","journal-title":"Neuroscience"},{"key":"10.1016\/j.bcp.2023.115522_b0260","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s12017-011-8155-9","article-title":"Oxidative stress and \u03b2-amyloid protein in Alzheimer\u2019s disease","volume":"13","author":"Cai","year":"2011","journal-title":"NeuroMol. Med."},{"key":"10.1016\/j.bcp.2023.115522_b0265","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1471-4159.2008.05347.x","article-title":"Amyloid beta peptide and NMDA induce ROS from NADPH oxidase and AA release from cytosolic phospholipase A2 in cortical neurons","volume":"106","author":"Shelat","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bcp.2023.115522_b0270","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1196\/annals.1306.012","article-title":"Redox-active metals, oxidative stress, and Alzheimer\u2019s disease pathology","volume":"1012","author":"Huang","year":"2004","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.bcp.2023.115522_b0275","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1042\/BJ20140772","article-title":"Redox proteomics analysis to decipher the neurobiology of Alzheimer-like neurodegeneration: Overlaps in Down\u2019s syndrome and Alzheimer\u2019s disease brain","volume":"463","author":"Butterfield","year":"2014","journal-title":"Biochem. J"},{"key":"10.1016\/j.bcp.2023.115522_b0280","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1089\/ars.2012.5027","article-title":"Amyloid \u03b2-Peptide (1\u201342)-induced oxidative stress in alzheimer disease: Importance in disease pathogenesis and progression","volume":"19","author":"Butterfield","year":"2013","journal-title":"Antioxidants Redox Signal"},{"key":"10.1016\/j.bcp.2023.115522_b0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/life11080767","article-title":"Oxidative stress and the neurovascular unit","volume":"11","author":"Rinaldi","year":"2021","journal-title":"Life"},{"key":"10.1016\/j.bcp.2023.115522_b0290","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1146\/annurev-immunol-051116-052358","article-title":"Microglia function in the central nervous system during health and neurodegeneration","volume":"35","author":"Colonna","year":"2017","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.bcp.2023.115522_b0295","first-page":"1","article-title":"311. Microglia in Alzheimer \u2019 s disease","volume":"2014","author":"Hansen","year":"2014","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.bcp.2023.115522_b0300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40035-020-00221-2","article-title":"Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes","volume":"9","author":"Kwon","year":"2020","journal-title":"Transl Neurodegener"},{"key":"10.1016\/j.bcp.2023.115522_b0305","doi-asserted-by":"crossref","unstructured":"C.A. Ju\u017awik, S. Drake, Y. Zhang, N. Paradis-Isler, A. Sylvester, A. Amar-Zifkin, C. Douglas, B. Morquette, C.S. Moore, A.E. Fournier, microRNA dysregulation in neurodegenerative diseases: A systematic review. Prog Neurobiol 182 (2019) 101664.","DOI":"10.1016\/j.pneurobio.2019.101664"},{"key":"10.1016\/j.bcp.2023.115522_b0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2021.147291","article-title":"Contribution of astrocytes to neuropathology of neurodegenerative diseases","volume":"1758","author":"Acioglu","year":"2021","journal-title":"Brain Res."},{"key":"10.1016\/j.bcp.2023.115522_b0315","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41593-020-00783-4","article-title":"Reactive astrocyte nomenclature, definitions, and future directions","volume":"24","author":"Escartin","year":"2021","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.bcp.2023.115522_b0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2021.104956","article-title":"Astrocyte subtype-specific approach to Alzheimer\u2019s disease treatment","volume":"145","author":"Sarkar","year":"2021","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.bcp.2023.115522_b0325","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S1474-4422(18)30490-3","article-title":"The role of astroglia in Alzheimer\u2019s disease: pathophysiology and clinical implications","volume":"18","author":"Arranz","year":"2019","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.bcp.2023.115522_b0330","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.neuro.2019.11.006","article-title":"Role of monocarboxylate transporter 4 in Alzheimer disease","volume":"76","author":"Hong","year":"2020","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.bcp.2023.115522_b0335","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1002\/jnr.24140","article-title":"Neuroprotective potential of astroglia","volume":"95","author":"Liu","year":"2017","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.bcp.2023.115522_b0340","doi-asserted-by":"crossref","first-page":"6910","DOI":"10.1007\/s12035-015-9567-6","article-title":"Disruption of TCA Cycle and Glutamate Metabolism Identified by Metabolomics in an In Vitro Model of Amyotrophic Lateral Sclerosis","volume":"53","author":"Veyrat-Durebex","year":"2016","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.bcp.2023.115522_b0345","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnagi.2018.00114","article-title":"Deciphering the astrocyte reaction in Alzheimer\u2019s disease","volume":"10","author":"Perez-Nievas","year":"2018","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.bcp.2023.115522_b0350","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1021\/acschemneuro.9b00333","article-title":"Understanding the Role of Systemic Inflammation in Alzheimer\u2019s Disease","volume":"10","author":"Walker","year":"2019","journal-title":"ACS Chem. Nerosci."},{"key":"10.1016\/j.bcp.2023.115522_b0355","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s11243-012-9583-6","article-title":"Redox active metal-induced oxidative stress in biological systems","volume":"37","author":"Jomova","year":"2012","journal-title":"Transit. Met. Chem."},{"key":"10.1016\/j.bcp.2023.115522_b0360","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1039\/C7MT00143F","article-title":"The transferrin receptor: The cellular iron gate","volume":"9","author":"Gammella","year":"2017","journal-title":"Metallomics"},{"key":"10.1016\/j.bcp.2023.115522_b0365","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.bbagen.2019.06.010","article-title":"Iron homeostasis and iron-regulated ROS in cell death, senescence and human diseases","volume":"1863","author":"Nakamura","year":"2019","journal-title":"Biochim Biophys Acta - Gen Subj"},{"key":"10.1016\/j.bcp.2023.115522_b0370","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1146\/annurev-nutr-082117-051749","article-title":"Crossing the iron gate: Why and how transferrin receptors mediate viral entry","volume":"38","author":"Wessling-Resnick","year":"2018","journal-title":"Annu. Rev. Nutr."},{"key":"10.1016\/j.bcp.2023.115522_b0375","doi-asserted-by":"crossref","first-page":"9090","DOI":"10.1523\/JNEUROSCI.1357-09.2009","article-title":"Impaired balance of mitochondrial fission and fusion in Alzheimer\u2019s disease","volume":"29","author":"Wang","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bcp.2023.115522_b0380","doi-asserted-by":"crossref","first-page":"9057","DOI":"10.1523\/JNEUROSCI.1469-06.2006","article-title":"Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer\u2019s disease brain is associated with mitochondrial dysfunction","volume":"26","author":"Devi","year":"2006","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bcp.2023.115522_b0385","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2019.00902","article-title":"Mitochondria as potential targets in Alzheimer disease therapy: An update","volume":"10","author":"Cenini","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2023.115522_b0390","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/antiox10081231","article-title":"Linking oxidative stress and proteinopathy in alzheimer\u2019s disease","volume":"10","author":"Sharma","year":"2021","journal-title":"Antioxidants"},{"key":"10.1016\/j.bcp.2023.115522_b0395","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1007\/s00018-016-2194-1","article-title":"Mechanisms of ferroptosis","volume":"73","author":"Cao","year":"2016","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.bcp.2023.115522_b0400","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2020.00239","article-title":"Ferroptosis and Its Potential Role in Human Diseases","volume":"11","author":"Han","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2023.115522_b0405","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.tips.2017.02.005","article-title":"Ferroptosis Inhibition: Mechanisms and Opportunities","volume":"38","author":"Angeli","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bcp.2023.115522_b0410","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-019-0720-y","article-title":"Ferroptosis, a new form of cell death: Opportunities and challenges in cancer","volume":"12","author":"Mou","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bcp.2023.115522_b0415","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.chembiol.2020.03.013","article-title":"The Chemistry and Biology of Ferroptosis","volume":"27","author":"Stockwell","year":"2020","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.bcp.2023.115522_b0420","doi-asserted-by":"crossref","DOI":"10.1038\/s41420-021-00579-w","article-title":"Ferroptosis: a cell death connecting oxidative stress, inflammation and cardiovascular diseases","author":"Yu","year":"2021","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.bcp.2023.115522_b0425","doi-asserted-by":"crossref","unstructured":"J. Li, F. Cao, H. Yin liang, Z jian. Huang, Z tao Lin, N. Mao, B. Sun, G. Wang, Ferroptosis: past, present and future. Cell Death Dis., 2020 https:\/\/doi.org\/10.1038\/s41419-020-2298-2.","DOI":"10.1038\/s41419-020-2298-2"},{"key":"10.1016\/j.bcp.2023.115522_b0430","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1093\/humrep\/deaa363","article-title":"Erastin induces ferroptosis via ferroportin-mediated iron accumulation in endometriosis","volume":"36","author":"Li","year":"2021","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.bcp.2023.115522_b0435","first-page":"3826","article-title":"Knockdown of ferroportin accelerates erastin-induced ferroptosis in neuroblastoma cells","volume":"22","author":"Geng","year":"2021","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.bcp.2023.115522_b0440","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/cdd.2015.158","article-title":"Ferroptosis: Process and function","volume":"23","author":"Xie","year":"2016","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.bcp.2023.115522_b0445","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","article-title":"Ferroptosis: An iron-dependent form of nonapoptotic cell death","volume":"149","author":"Dixon","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2023.115522_b0450","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/jnc.15519","article-title":"Ferroptosis as a mechanism of neurodegeneration in Alzheimer\u2019s disease","volume":"159","author":"Jakaria","year":"2021","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bcp.2023.115522_b0455","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20194968","article-title":"Programmed cell-death by ferroptosis: Antioxidants as mitigators","author":"Kajarabille","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2023.115522_b0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101494","article-title":"Iron dyshomeostasis, lipid peroxidation and perturbed expression of cystine\/glutamate antiporter in Alzheimer\u2019s disease: Evidence of ferroptosis","volume":"32","author":"Ashraf","year":"2020","journal-title":"Redox Biol."},{"key":"10.1016\/j.bcp.2023.115522_b0465","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.neurobiolaging.2017.10.017","article-title":"Postmortem MRI and histology demonstrate differential iron accumulation and cortical myelin organization in early- and late-onset Alzheimer\u2019s disease","volume":"62","author":"Bulk","year":"2018","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.bcp.2023.115522_b0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108373","article-title":"Molecular mechanisms of ferroptosis and their involvement in brain diseases","author":"Costa","year":"2023","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2023.115522_b0475","doi-asserted-by":"crossref","first-page":"6156","DOI":"10.1007\/s12035-019-1500-y","article-title":"Systematic Review of miRNA as Biomarkers in Alzheimer\u2019s Disease","volume":"56","author":"Swarbrick","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.bcp.2023.115522_b0480","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41380-020-0721-9","article-title":"Biomarkers for Alzheimer\u2019s disease\u2014preparing for a new era of disease-modifying therapies","volume":"26","author":"Zetterberg","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.bcp.2023.115522_b0485","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.neuroscience.2017.07.017","article-title":"Biomarkers for Alzheimer Disease: Classical and Novel Candidates\u2019 Review","volume":"370","author":"El Kadmiri","year":"2018","journal-title":"Neuroscience"},{"key":"10.1016\/j.bcp.2023.115522_b0490","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","article-title":"Biomarkers for neurodegenerative diseases","volume":"27","author":"Hansson","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2023.115522_b0495","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.3233\/JAD-170156","article-title":"Identification of circulating miR-125b as a potential biomarker of Alzheimer\u2019s disease in APP\/PS1 transgenic mouse","volume":"59","author":"Hong","year":"2017","journal-title":"J Alzheimer\u2019s Dis"},{"key":"10.1016\/j.bcp.2023.115522_b0500","doi-asserted-by":"crossref","DOI":"10.1038\/s41398-020-01184-8","article-title":"MiRNA-15b and miRNA-125b are associated with regional A\u03b2-PET and FDG-PET uptake in cognitively normal individuals with subjective memory complaints","author":"Vergallo","year":"2021","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.bcp.2023.115522_b0505","first-page":"1","article-title":"Neurofilament light chain as a biomarker in neurological disorders","author":"Gaetani","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.bcp.2023.115522_b0510","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2010.07.002","article-title":"Volumetic and visual rating of MRI scans in the diagnosis of amnestic MCI and Alzheimer\u2019s disease","volume":"7","author":"Shen","year":"2011","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.bcp.2023.115522_b0515","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnins.2022.787404","article-title":"PET Imaging of Synaptic Density: Challenges and Opportunities of Synaptic Vesicle Glycoprotein 2A PET in Small Animal Imaging","volume":"16","author":"Toyonaga","year":"2022","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.bcp.2023.115522_b0520","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13024-018-0298-9","article-title":"New insights into the role of TREM2 in Alzheimer\u2019s disease","volume":"13","author":"Gratuze","year":"2018","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.bcp.2023.115522_b0525","doi-asserted-by":"crossref","first-page":"20","DOI":"10.5483\/BMBRep.2020.53.1.273","article-title":"Translocator protein (TSPO): The new story of the old protein in neuroinflammation","volume":"53","author":"Lee","year":"2020","journal-title":"BMB Rep."},{"key":"10.1016\/j.bcp.2023.115522_b0530","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/s41582-018-0079-7","article-title":"Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic","volume":"14","author":"Hampel","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.bcp.2023.115522_b0535","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15252\/emmm.201911170","article-title":"Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer\u2019s disease","volume":"11","author":"Palmqvist","year":"2019","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.bcp.2023.115522_b0540","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S1474-4422(21)00214-3","article-title":"Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer\u2019s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study","volume":"20","author":"Thijssen","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.bcp.2023.115522_b0545","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/joim.12816","article-title":"Biomarkers for Alzheimer\u2019s disease: current status and prospects for the future","volume":"284","author":"Blennow","year":"2018","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.bcp.2023.115522_b0550","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-24319-x","article-title":"Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer\u2019s disease in adults with Down syndrome","volume":"12","author":"Lle\u00f3","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2023.115522_b0555","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/alz.12236","article-title":"Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer\u2019s disease diagnosis","volume":"17","author":"Karikari","year":"2021","journal-title":"Alzheimer\u2019s Dement"},{"key":"10.1016\/j.bcp.2023.115522_b0560","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.pneurobio.2015.12.003","article-title":"Multitarget compounds bearing tacrine- and donepezil-like structural and functional motifs for the potential treatment of Alzheimer\u2019s disease","volume":"151","author":"Ismaili","year":"2017","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.bcp.2023.115522_b0565","doi-asserted-by":"crossref","unstructured":"J. Weller, A. Budson, Current understanding of Alzheimer\u2019s disease diagnosis and treatment. F1000Research 7 (2018) 1\u20139.","DOI":"10.12688\/f1000research.14506.1"},{"key":"10.1016\/j.bcp.2023.115522_b0570","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.3233\/JAD-179901","article-title":"Clinical Trials for Disease-Modifying Therapies in Alzheimer\u2019s Disease: A Primer, Lessons Learned, and a Blueprint for the Future","volume":"64","author":"Cummings","year":"2018","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"10.1016\/j.bcp.2023.115522_b0575","first-page":"1","article-title":"Cummings, Jeffrey L_Alzheimer\u2019s_drug development candidates failures_2014","volume":"6","author":"Cummings","year":"2014","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.bcp.2023.115522_b0580","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ejmech.2017.03.062","article-title":"Recent progress in the identification of selective butyrylcholinesterase inhibitors for Alzheimer\u2019s disease","volume":"132","author":"Li","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2023.115522_b0585","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.bioorg.2018.01.017","article-title":"Synthesis and structure-activity relationship study of multi-target triazine derivatives as innovative candidates for treatment of Alzheimer\u2019s disease","volume":"77","author":"Iraji","year":"2018","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bcp.2023.115522_b0590","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2020.112350","article-title":"New deferiprone derivatives as multi-functional cholinesterase inhibitors: design, synthesis and in vitro evaluation","volume":"198","author":"Bortolami","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2023.115522_b0595","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ijbiomac.2019.02.156","article-title":"Nanoparticle formulations in the diagnosis and therapy of Alzheimer\u2019s disease","volume":"130","author":"Gupta","year":"2019","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.bcp.2023.115522_b0600","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.neulet.2006.07.020","article-title":"Nanoparticle iron chelators: A new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance","volume":"406","author":"Liu","year":"2006","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bcp.2023.115522_b0605","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1039\/c0nr00875c","article-title":"Pharmacological potential of cerium oxide nanoparticles","volume":"3","author":"Celardo","year":"2011","journal-title":"Nanoscale"},{"key":"10.1016\/j.bcp.2023.115522_b0610","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1021\/acsnano.5b08045","article-title":"Mitochondria-Targeting Ceria Nanoparticles as Antioxidants for Alzheime\u0155s Disease","volume":"10","author":"Kwon","year":"2016","journal-title":"ACS Nano"},{"key":"10.1016\/j.bcp.2023.115522_b0615","doi-asserted-by":"crossref","DOI":"10.1016\/j.impact.2020.100251","article-title":"Nanomaterials for the treatment and diagnosis of Alzheimer\u2019s disease: An overview","volume":"20","author":"Bilal","year":"2020","journal-title":"NanoImpact"},{"key":"10.1016\/j.bcp.2023.115522_b0620","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41582-018-0013-z","article-title":"Tau-targeting therapies for Alzheimer disease","volume":"14","author":"Congdon","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.bcp.2023.115522_b0625","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00401-017-1707-9","article-title":"Roles of tau protein in health and disease","volume":"133","author":"Guo","year":"2017","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.bcp.2023.115522_b0630","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103691","article-title":"Antisense oligonucleotides for Alzheimer\u2019s disease therapy: from the mRNA to miRNA paradigm","volume":"74","author":"Grabowska-Pyrzewicz","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.bcp.2023.115522_b0635","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173554","article-title":"Alzheimer\u2019s disease: Recent treatment strategies","volume":"887","author":"Vaz","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bcp.2023.115522_b0640","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1038\/s41386-018-0178-6","article-title":"Memory enhancing effects of BPN14770, an allosteric inhibitor of phosphodiesterase-4D, in wild-type and humanized mice","volume":"43","author":"Zhang","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bcp.2023.115522_b0645","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41582-018-0116-6","article-title":"A critical appraisal of amyloid-\u03b2-targeting therapies for Alzheimer disease","volume":"15","author":"Panza","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.bcp.2023.115522_b0650","first-page":"1","article-title":"The AHEAD 3\u201345 Study: Design of a prevention trial for Alzheimer\u2019s disease","author":"Rafii","year":"2022","journal-title":"Alzheimer\u2019s Dement"},{"key":"10.1016\/j.bcp.2023.115522_b0655","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s12035-021-02617-1","article-title":"Delineation of Neuroprotective Effects and Possible Benefits of AntioxidantsTherapy for the Treatment of Alzheimer\u2019s Diseases by Targeting Mitochondrial-Derived Reactive Oxygen Species: Bench to Bedside","volume":"59","author":"Walia","year":"2022","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.bcp.2023.115522_b0660","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.fshw.2021.12.006","article-title":"Multifaceted neuroprotective effects of (-)-epigallocatechin-3-gallate (EGCG) in Alzheimer\u2019s disease: an overview of pre-clinical studies focused on \u03b2-amyloid peptide","volume":"11","author":"Youn","year":"2022","journal-title":"Food Sci. Hum. Wellness"},{"key":"10.1016\/j.bcp.2023.115522_b0665","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctim.2019.102294","article-title":"Oxidative stress in alzheimer\u2019s disease: A review on emergent natural polyphenolic therapeutics","volume":"49","author":"Cassidy","year":"2020","journal-title":"Complement. Ther. Med."},{"key":"10.1016\/j.bcp.2023.115522_b0670","doi-asserted-by":"crossref","unstructured":"F. He, X. Ru, T. Wen, NRF2 , a Transcription Factor for Stress Response and Beyond. 1\u201323 (2020).","DOI":"10.3390\/ijms21134777"},{"key":"10.1016\/j.bcp.2023.115522_b0675","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cells10081884","article-title":"Role of nrf2 in synaptic plasticity and memory in alzheimer\u2019s disease","volume":"10","author":"Davies","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.bcp.2023.115522_b0680","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.apsb.2020.01.015","article-title":"Gene therapy for neurodegenerative disorders: advances, insights and prospects","volume":"10","author":"Chen","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bcp.2023.115522_b0685","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1007\/s12035-021-02638-w","article-title":"CRISPR-Cas9-Mediated Gene Therapy in Neurological Disorders","volume":"59","author":"Guan","year":"2022","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.bcp.2023.115522_b0690","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.trci.2018.11.001","article-title":"A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer\u2019s disease","volume":"5","author":"Grundman","year":"2019","journal-title":"Alzheimer\u2019s Dement Transl. Res. Clin. Interv."},{"key":"10.1016\/j.bcp.2023.115522_b0695","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1002\/alz.12302","article-title":"Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer\u2019s disease modification","volume":"17","author":"Izzo","year":"2021","journal-title":"Alzheimer\u2019s Dement"},{"key":"10.1016\/j.bcp.2023.115522_b0700","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25225439","article-title":"Sigma-2 receptor\u2014a potential target for cancer\/alzheimer\u2019s disease treatment via its regulation of cholesterol homeostasis","author":"Yang","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.bcp.2023.115522_b0705","first-page":"523","article-title":"Aging","volume":"3","author":"Behfar","year":"2022","journal-title":"Senescence, and Dementia."},{"key":"10.1016\/j.bcp.2023.115522_b0710","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.trsl.2020.06.007","article-title":"Cellular senescence in age-related disorders","volume":"226","author":"Kaur","year":"2020","journal-title":"Transl. Res."},{"key":"10.1016\/j.bcp.2023.115522_b0715","doi-asserted-by":"crossref","unstructured":"R. Liu, Aging , Cellular Senescence , and Alzheimer \u2019 s Disease (2022).","DOI":"10.3390\/ijms23041989"},{"key":"10.1016\/j.bcp.2023.115522_b0720","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-25453-2","article-title":"Long-term treatment with senolytic drugs Dasatinib and Quercetin ameliorates age-dependent intervertebral disc degeneration in mice","volume":"12","author":"Novais","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2023.115522_b0725","doi-asserted-by":"crossref","first-page":"22","DOI":"10.14283\/jpad.2021.62","article-title":"Senolytic Therapy to Modulate the Progression of Alzheimer\u2019s Disease (SToMP-AD): A Pilot Clinical Trial","volume":"9","author":"Gonzales","year":"2022","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"10.1016\/j.bcp.2023.115522_b0730","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.tins.2021.06.007","article-title":"Cellular senescence at the crossroads of inflammation and Alzheimer\u2019s disease","volume":"44","author":"Guerrero","year":"2021","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.bcp.2023.115522_b0735","doi-asserted-by":"crossref","DOI":"10.1111\/acel.12840","article-title":"Tau protein aggregation is associated with cellular senescence in the brain","author":"Musi","year":"2018","journal-title":"Aging Cell"},{"key":"10.1016\/j.bcp.2023.115522_b0740","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.ebiom.2018.12.052","article-title":"Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study","volume":"40","author":"Justice","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.bcp.2023.115522_b0745","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/alz.057581","article-title":"Safety and efficacy of Lomecel-B in patients with mild Alzheimer\u2019s disease: Results of a double-blinded, randomized, placebo-controlled phase 1 clinical trial","volume":"17","author":"Oliva","year":"2021","journal-title":"Alzheimer\u2019s Dement"},{"key":"10.1016\/j.bcp.2023.115522_b0750","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/alz.12651","article-title":"Results and insights from a phase I clinical trial of Lomecel-B for Alzheimer\u2019s disease","volume":"19","author":"Brody","year":"2023","journal-title":"Alzheimer\u2019s Dement"},{"key":"10.1016\/j.bcp.2023.115522_b0755","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/joim.13141","article-title":"Senolytic drugs: from discovery to translation","volume":"288","author":"Kirkland","year":"2020","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.bcp.2023.115522_b0760","first-page":"1","article-title":"Alzheimer\u2019s disease drug development pipeline: 2021","volume":"7","author":"Cummings","year":"2021","journal-title":"Alzheimer\u2019s Dement Transl. Res. Clin. Interv."},{"key":"10.1016\/j.bcp.2023.115522_b0765","doi-asserted-by":"crossref","first-page":"787","DOI":"10.4252\/wjsc.v12.i8.787","article-title":"Stem cell therapy for alzheimer\u2019s disease","volume":"12","author":"Liu","year":"2020","journal-title":"World J. Stem Cells"},{"key":"10.1016\/j.bcp.2023.115522_b0770","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/brb3.2740","article-title":"A review of stem cell therapy: An emerging treatment for dementia in Alzheimer\u2019s and Parkinson\u2019s disease","volume":"12","author":"Pradhan","year":"2022","journal-title":"Brain Behav."},{"key":"10.1016\/j.bcp.2023.115522_b0775","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/life13010001","article-title":"The Allosteric Antagonist of the Sigma-2 Receptors\u2014Elayta (CT1812) as a Therapeutic Candidate for Mild to Moderate Alzheimer\u2019s Disease: A Scoping Systematic Review","volume":"13","author":"Rasheed","year":"2023","journal-title":"Life"},{"key":"10.1016\/j.bcp.2023.115522_b0780","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1021\/acsmedchemlett.1c00048","article-title":"Discovery of Investigational Drug CT1812, an Antagonist of the Sigma-2 Receptor Complex for Alzheimer\u2019s Disease","volume":"12","author":"Rishton","year":"2021","journal-title":"ACS Med. Chem. Lett."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295223001132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295223001132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:42:38Z","timestamp":1757770958000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295223001132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":156,"alternative-id":["S0006295223001132"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2023.115522","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alzheimer\u2019s disease: Insights and new prospects in disease pathophysiology, biomarkers and disease-modifying drugs","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2023.115522","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"115522"}}